Calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Revenues1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 15, 2023 | 2.93 | = | 227.03 | ÷ | 77.59 | 77.59 | = | 14,410 | ÷ | 185,722,621 | |
| Feb 16, 2022 | 3.19 | = | 232.18 | ÷ | 72.84 | 72.84 | = | 13,874 | ÷ | 190,485,264 | |
| Feb 12, 2021 | 3.24 | = | 192.66 | ÷ | 59.38 | 59.38 | = | 11,359 | ÷ | 191,281,286 | |
| Feb 18, 2020 | 2.87 | = | 165.42 | ÷ | 57.65 | 57.65 | = | 11,088 | ÷ | 192,339,093 | |
| Feb 19, 2019 | 2.69 | = | 141.49 | ÷ | 52.69 | 52.69 | = | 10,412 | ÷ | 197,599,861 | |
| Feb 16, 2018 | 2.18 | = | 101.72 | ÷ | 46.77 | 46.77 | = | 9,739 | ÷ | 208,251,468 | |
| Feb 16, 2017 | 2.63 | = | 76.87 | ÷ | 29.18 | 29.18 | = | 6,878 | ÷ | 235,719,111 | |
| Feb 11, 2016 | 1.23 | = | 59.00 | ÷ | 48.06 | 48.06 | = | 5,738 | ÷ | 119,384,993 | |
| Feb 12, 2015 | 1.44 | = | 63.25 | ÷ | 43.92 | 43.92 | = | 5,460 | ÷ | 124,315,113 | |
| Feb 13, 2014 | 1.33 | = | 52.20 | ÷ | 39.27 | 39.27 | = | 5,100 | ÷ | 129,842,707 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of IQVIA Holdings Inc. Annual Report.
The valuation of the company, as measured by the Price-to-Sales (P/S) ratio, exhibits a distinct transition between two valuation regimes from 2014 to 2023. An initial period of relative stability was followed by a significant expansion in the multiple, which peaked in 2021 before entering a phase of gradual compression.
- Price-to-Sales Ratio Evolution
- Between February 2014 and February 2016, the P/S ratio remained relatively low and stable, ranging between 1.23 and 1.44. A sharp increase occurred in February 2017, with the ratio jumping to 2.63. This established a new, higher valuation baseline. The ratio continued a general upward trajectory, reaching its zenith of 3.24 in February 2021, followed by a slight decline to 2.93 by February 2023.
- Share Price and Revenue Dynamics
- The share price experienced sustained growth over the analyzed period, increasing from 52.20 in 2014 to a peak of 232.18 in 2022. While sales per share also grew from 39.27 in 2014 to 77.59 in 2023, the rate of share price appreciation significantly exceeded the growth rate of sales. This divergence is the primary driver behind the expansion of the P/S multiple.
- Valuation Divergence in 2017
- A significant anomaly is observed in February 2017, where the P/S ratio climbed to 2.63 despite a marked decrease in sales per share, which fell to 29.18 from 48.06 the previous year. This suggests a fundamental shift in market perception, where the company began to be valued at a higher premium per unit of revenue regardless of the temporary decline in sales per share.
- Recent Valuation Trends
- Since February 2021, a trend of slight valuation cooling is evident. The P/S ratio declined from 3.24 to 2.93 over two years. This contraction occurred despite sales per share continuing to rise from 59.38 to 77.59, indicating that the market is normalizing the premium it is willing to pay for the company's revenue stream.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Comparison to Competitors
| IQVIA Holdings Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 15, 2023 | 2.93 | 4.61 | 5.17 | 3.29 | 5.79 | 10.96 | 3.86 | 4.34 | 4.71 | 2.35 | 7.01 | 4.73 | 8.56 |
| Feb 16, 2022 | 3.19 | 4.53 | 5.10 | 3.16 | 6.37 | 8.01 | 2.85 | 4.66 | 3.96 | 3.15 | 4.20 | 5.39 | 8.21 |
| Feb 12, 2021 | 3.24 | 4.05 | 5.64 | 3.16 | 7.01 | 8.06 | 3.24 | 5.15 | 3.93 | 4.42 | 6.24 | 5.52 | 8.82 |
| Feb 18, 2020 | 2.87 | 4.22 | 6.03 | 5.52 | 6.29 | 6.03 | 4.00 | 4.79 | 4.33 | 3.66 | 5.34 | 4.83 | 14.95 |
| Feb 19, 2019 | 2.69 | 3.58 | 5.22 | 3.67 | 3.97 | 5.15 | 3.84 | 4.45 | 4.92 | 4.49 | 6.62 | 4.24 | 15.54 |
| Feb 16, 2018 | 2.18 | 6.67 | 5.82 | 5.02 | 3.70 | 3.71 | 4.10 | 4.56 | 3.68 | 4.05 | 5.92 | 4.01 | 16.42 |
| Feb 16, 2017 | 2.63 | 3.84 | 5.65 | 4.72 | 3.48 | 4.18 | 3.08 | 4.62 | 4.54 | 3.84 | 7.86 | 3.37 | 12.51 |
| Feb 11, 2016 | 1.23 | 3.83 | 5.28 | 6.07 | 2.91 | 4.02 | 3.80 | 4.13 | 3.56 | 3.76 | 9.38 | 3.05 | 20.38 |
| Feb 12, 2015 | 1.44 | 4.90 | 6.13 | 6.28 | 3.09 | 4.03 | 6.36 | 3.77 | 3.93 | 4.24 | 14.62 | 3.06 | 47.41 |
| Feb 13, 2014 | 1.33 | 4.31 | 5.22 | 5.48 | 2.78 | 2.81 | 11.95 | 3.63 | 3.78 | 3.97 | 15.52 | 3.74 | 16.53 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
IQVIA Holdings Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| IQVIA Holdings Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 15, 2023 | 2.93 | 4.56 |
| Feb 16, 2022 | 3.19 | 4.50 |
| Feb 12, 2021 | 3.24 | 4.90 |
| Feb 18, 2020 | 2.87 | 4.88 |
| Feb 19, 2019 | 2.69 | 4.54 |
| Feb 16, 2018 | 2.18 | 4.60 |
| Feb 16, 2017 | 2.63 | 4.29 |
| Feb 11, 2016 | 1.23 | 4.10 |
| Feb 12, 2015 | 1.44 | 4.54 |
| Feb 13, 2014 | 1.33 | 4.30 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Industry (Health Care)
| IQVIA Holdings Inc. | Health Care | |
|---|---|---|
| Feb 15, 2023 | 2.93 | 51,413.66 |
| Feb 16, 2022 | 3.19 | 3.28 |
| Feb 12, 2021 | 3.24 | 3.31 |
| Feb 18, 2020 | 2.87 | 3.21 |
| Feb 19, 2019 | 2.69 | 3.07 |
| Feb 16, 2018 | 2.18 | 3.06 |
| Feb 16, 2017 | 2.63 | 2.80 |
| Feb 11, 2016 | 1.23 | 2.72 |
| Feb 12, 2015 | 1.44 | 3.08 |
| Feb 13, 2014 | 1.33 | 2.81 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).